This is an example of a typical bladder control treatment pathway for a patient who is seeking treatment for symptoms of urge-incontinence and/or urgency-frequency.¹

**EVALUATION**

Incontinence
Urgency
Frequency

**CONSERVATIVE THERAPIES**

- Bladder Training
- Fluid Management
- Pelvic Floor Muscle Training
- Bladder Control Strategies

**RE-EVALUATION**

Medications (4-8 Weeks)

**RE-EVALUATION**

**ADVANCED THERAPIES**

- Percutaneous Tibial Neuromodulation (PTNM)
- Sacral Neuromodulation (SNM)
- BOTOX® (onabotulinumtoxinA)

*BOLOX® is a registered trademark of Allergan, Inc.*
REFERENCE


**Indication for Use:** Medtronic NURO™ Percutaneous Tibial Neuromodulation is intended to treat patients with overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.

**Contraindications:** Do not use on patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function, or on patients who are pregnant or planning pregnancy. Warnings/Precautions/Adverse Events: Do not use if the skin in the area of use is compromised. Exercise caution for patients with heart problems. Adverse events are typically temporary, and include mild pain, minor inflammation and bleeding near treatment site.

For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic’s website at professional.medtronic.com/NURO. Product technical manual must be reviewed prior to use for detailed disclosure.

USA Rx only. Rev 0915

**InterStim® Therapy for Urinary Control** is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

**Contraindications:** Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

**Warning:** This therapy is not intended for patients with mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture.

**Warnings/Precautions/Adverse Events:** Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins such as multiple sclerosis. The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic’s website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.

USA Rx Only. Rev 0815